INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use

Inclusion Criteria: 1. Aged 18 years or older at study enrolment. 2. Fulfilled the 2019 EULAR/ACR criteria1 for SLE at the time of study entry. 3. Prescribed anifrolumab for their SLE treatment for the first time, according to approved country-specific label. 4. It is important to note that a physician decision to prescribe anifrolumab will need to occur prior to any study-related discussion. 5. In countries where prescription reimbursements are authorized on a case-by-case basis, authorization (ie, patient access to treatment) will be required for study entry. 6. Provided informed consent to participate in the study. 7. Willing and able to participate in all required study evaluations and procedures. Exclusion Criteria: 1. Currently participating in an anifrolumab early access/compassionate use program or an interventional clinical trial with an investigational product. 2. Previous exposure to anifrolumab as part of a clinical trial or early access program. 3. Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy (mycophenolate mofetil \[MMF\]/cyclophosphamide \[CYC\] + high dose steroids), isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus. 4. Any other condition which the investigator deems to limit a patient's ability to understand the informed consent or complete the PROs.